15Mio+ images analyzed

600+ clinical installations

40+ countries worldwide

200+ scientific papers

Our customers and innovation partners

In cooperation with Thirona, we can offer Pharma and Med-Tech companies the most advanced and well validated quantitative measurements tailored to the needs of each clinical trial.

Clinical Research Organization

United States

The unique combination of medical and technical knowledge, and Thirona’s focus on real clinical problems, allows us to innovate our product faster and with higher performance.

Multinational MedTech Company

The Netherlands

Thirona's AI solutions provide highly precise quantitative information of the lungs which is of invaluable importance
for planning complex bronchoscopic interventions in our clinic.

Prof. Interventional Pulmonology

The Netherlands

Our Expertise

High-precision analysis of lung anatomical structures and disease distribution

Advancing Pharmaceutical Treatment Development

Comprehensive clinical trial services, from study design and inclusion criteria to translation to clinical practice.

Transforming Bronchoscopic and Surgical Interventions

Enabling innovation along the complete clinical intervention pathway.

Aiding Clinicians in Daily Patient Care

Solutions for reliable and fast diagnosis, quantification of pulmonary pathologies and monitoring of chronic lung diseases.

Knowledge, quality and service with proven technology

Advanced multi-level measurements

Sophisticated quantitative measures, from global to localized disease patterns

Highly accurate quantifications

Unique segmentation capabilities with double-review by human analysts

Scalable technology platform

Consistent quality from specialized studies to large scale trials

Scientific & clinical validation

Wide range of validated deep learning models for major and rare pathologies

Ready to apply AI image analysis to get better outcomes faster?

Let us help you find the perfect solution!

Talk to one of our experts to learn more.

Research & Innovation Projects

  • European initiative to standardize QCT metrics in CF population data

  • Global consortium for development of respiratory digital imaging biomarkers

  • Collaborative European research in non-Cystic Fibrosis bronchiectasis

Papers & Publications

    • Elexacaftor/tezacafor/ivacaftor improves bronchial dilatation in a real-world cohort of adolescents with cystic fibrosis | Aug 2025 | Journal of Cystic Fibrosis
    • Measuring segmental lung changes of Cystic Fibrosis patients before and after Elexacaftor-Tezacaftor-Ivacaftor (ETI) with an automated analysis method | Journal of Cystic Fibrosis
    • Improvements in structural lung disease in people with CF aged 12 and above on Elexacaftor/Tezacaftor/Ivacaftor (ETI) are sustained for up to two years | Jul 2025 | Journal of Cystic Fibrosis